Minerva Neurosciences, Inc.
Business
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing proprietary product candidates for central nervous system diseases. Its lead program, roluperidone, targets negative symptoms in schizophrenia and is advancing toward a Phase 3 confirmatory trial following an FDA Complete Response Letter in February 2024. The company previously co-developed seltorexant with Janssen for insomnia and major depressive disorder, and sold royalty rights to that asset to Royalty Pharma in 2021. Minerva retains global commercialization rights for roluperidone except in certain Asian countries.
Summary from 10-K filed 2026-03-11
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 6 | 12 | 13 | 15 | 32 | |
| General and administrative | 9 | 10 | 10 | 11 | 13 | |
| Total expenses | 15 | 22 | 23 | 25 | 45 | |
| Loss from operations | −15 | −22 | −23 | −25 | −45 | |
| Foreign exchange losses | −56,555 | −1,926 | −40,235 | −27,741 | −32,846 | |
| Investment income | 948,122 | 1 | 1 | 556,946 | 16,516 | |
| Non-cash interest expense for the sale of future royalties | — | −5 | −8 | −7 | −6 | |
| Other income | — | 27 | — | — | — | |
| Loss on issuance of convertible preferred stock and warrants | −321 | — | — | — | — | |
| Warrant issuance cost | −3 | — | — | — | — | |
| Changes in fair value of the warrant liability | 45 | — | — | — | — | |
| Net (loss) income | −293 | 1 | −30 | −32 | −50 | |
| Net (loss) income per share, basic | −34.67 | 0.19 | −4.61 | −6.01 | −9.35 | |
| Weighted average shares outstanding, basic | 8 | 8 | 7 | 5 | 5 | |
| Net (loss) income per share, diluted | −34.67 | 0.19 | −4.61 | −6.01 | −9.35 | |
| Weighted average shares outstanding, diluted | 8 | 8 | 7 | 5 | 5 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 82 | 21 | 41 | 36 | 61 | |
| Restricted cash | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | |
| Prepaid expenses and other current assets | 697,676 | 806,895 | 989,865 | 848,117 | 1 | |
| Total current assets | 83 | 22 | 42 | 40 | 62 | |
| Equipment, net | 0 | 5,442 | 10,884 | 16,326 | — | |
| Goodwill | 15 | 15 | 15 | 15 | 15 | |
| Total assets | 98 | 37 | 57 | 55 | 77 | |
| Accounts payable | 639,707 | 2 | 2 | 969,667 | 2 | |
| Accrued expenses and other current liabilities | 2 | 1 | 2 | 407,909 | 965,739 | |
| Total current liabilities | 2 | 3 | 3 | 1 | 3 | |
| Warrant liability | 171 | 0 | — | — | — | |
| Liability related to the sale of future royalties | 60 | 60 | 82 | 74 | 66 | |
| Total liabilities | 234 | 63 | 85 | 75 | 69 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common stock; $0.0001 par value; 250,000,000 shares authorized; 43,274,398 shares issued and outstanding as of December 31, 2025 and 125,000,000 shares authorized; 6,993,406 shares issued and outstanding as of December 31, 2024 | 4,327 | 699 | 699 | 534 | 534 | |
| Additional paid-in capital | 548 | 370 | 368 | 347 | 343 | |
| Accumulated deficit | −689 | −395 | −397 | −367 | −335 | |
| Total stockholders' deficit | −141 | −26 | −28 | −20 | 8 | |
| Total liabilities, redeemable preferred stock and stockholders' deficit | 98 | 37 | 57 | 55 | 77 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net (loss) income | −293 | 1 | −30 | −32 | −50 | |
| Depreciation and amortization | 5,442 | 5,442 | 5,442 | — | — | |
| Amortization of capitalized software | — | 17,027 | 25,540 | 8,513 | — | |
| Stock-based compensation expense | 1 | 1 | 2 | 4 | 5 | |
| Non-cash interest expense associated with the sale of future royalties | — | 5 | 8 | 7 | 6 | |
| Remeasurement of liability related to sale of future royalties | — | −27 | — | — | — | |
| Prepaid expenses and other current assets | 109,219 | 182,970 | −141,748 | 498,242 | 636,905 | |
| Accounts payable | −1 | −197,476 | 835,653 | −883,548 | 857,601 | |
| Accrued expenses and other current liabilities | 317,446 | −306,097 | 1 | −557,830 | −1 | |
| Net cash used in operating activities | −14 | −20 | −15 | −25 | −25 | |
| Net cash provided by investing activities | 0 | 0 | 0 | −16,326 | — | |
| Proceeds from sales of common stock and warrants in private placement | 80 | — | 20 | — | — | |
| Costs paid in connection with private placement | −5 | — | −396,293 | — | — | |
| Payment of deferred offering costs | −155,948 | — | — | — | — | |
| Net cash provided by (used in) financing activities | 74 | — | 20 | −5 | 60 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 61 | −20 | 5 | −25 | 35 | |
| Initial recognition of warrant liability at fair value | 217 | — | — | — | — | |
| Deferred issuance costs included in accounts payable and accrued expenses | 195,195 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Minerva Neurosciences, Inc.'s CIK number?
Minerva Neurosciences, Inc.'s SEC CIK number is 0001598646 (1598646). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Minerva Neurosciences, Inc.'s SEC filings?
All of Minerva Neurosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Minerva Neurosciences, Inc. last report earnings?
Minerva Neurosciences, Inc. (NERV) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-205129). This is Minerva Neurosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Minerva Neurosciences, Inc.'s most recent earnings 8-K?
Minerva Neurosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-205129. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Minerva Neurosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →